NASDAQ$SIGA

SIGA Technologies, Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

SIGA Technologies reported strong Q1 2024 results with increased product revenues and pre-tax operating income.

SIGA Technologies reported a successful first quarter with product revenues reaching $24 million and pre-tax operating income of $11 million, both showing an increase compared to the same quarter in the previous year. The company remains focused on advancing its strategy, progressing clinical programs, and negotiating the next contract with the U.S. Government.

  • Generated product sales of $24 million.
  • Achieved pre-tax operating income of $11 million.
  • Delivered approximately $24 million of oral TPOXX to a diverse mix of customers.
  • A new drug application for tecovirimat (TPOXX) was filed in Japan for the treatment of smallpox, mpox, cowpox, and complications due to vaccinia virus.

Headline financials

Total Revenue

$25.4M

Previous: $8.32M+205.5%
EPS

$0.14

Previous: -$0.01+1500.0%
Basic Shares Outstanding

71.1M

No prior period
Diluted Shares Outstanding

71.6M

No prior period
Capital Expenditures

$0.00

Previous: $0.00
Free Cash Flow

$10.3M

Previous: -$918K+1219.2%
Net Income

$10.3M

Previous: -$918K+1219.2%
Operating Income

$11.3M

Previous: -$2.11M+634.8%
Gross Profit

$22.2M

Previous: $7.17M+209.6%
R&D Expense

$3.05M

No prior period
Stock-Based Comp

$1.13M

Previous: $409K+176.5%

Revenue & EPS history

SIGA Technologies · Revenue · Quarterly

$25.4M

Q1 2024+205.5%vs Q1 2023
Beat estimate in 0 of 3 quarters(0%)
ActualEstimate

Revenue by segment

SIGA Technologies · $9.24M total across 2 segments · Q3 2023

  • Product Sales
    $7.96M-87.9%
  • R&D Revenues
    $1.28M-80.6%

Forward guidance

SIGA Technologies remains committed to advancing its strategy and enhancing shareholder value as it looks forward to progressing its clinical programs, negotiating the next contract with the U.S. Government, and promoting public health.

Tailwinds

  • Progressing clinical programs.
  • Negotiating the next contract with the U.S. Government.
  • Promoting public health.
  • Greater control over international promotion activities.
  • Meeting global customers’ needs more effectively.

Headwinds

  • Risk that BARDA may not exercise all remaining unexercised options.
  • Risk that SIGA may not complete performance under the BARDA Contract on schedule.
  • Risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled.
  • Risk that the international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally.
  • Risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.2%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

26 / 64 earnings

Positive

+31.9%

Q4 2023

Best reaction

-27.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%-5.5%-8.5%
Q4 2025-3.0%-3.4%-22.8%
Q3 2025-20.2%-24.0%-24.1%
Q1 2025+4.4%+9.0%+10.8%
Q4 2024+7.0%+0.5%+6.4%
Q3 2024-1.9%-8.5%-9.8%
Q2 2024-12.8%-14.3%-9.5%
Q1 2024-27.8%-28.2%-26.7%
Q4 2023+31.9%+49.9%+88.3%
Q3 2023-4.4%-2.2%+16.9%
Q2 2023-3.7%-10.0%-21.9%
Q1 2023+5.1%+1.8%-0.7%
Q4 2022-3.8%-7.8%-13.4%
Q3 2022+7.5%+9.8%+1.1%
Q2 2022+27.4%+24.6%-21.0%
Q1 2022+3.6%+4.0%+60.7%
Q4 2021+3.0%+6.6%+22.4%
Q3 2021-0.7%+0.0%+2.8%
Q2 2021-2.9%-4.0%+9.1%
Q1 2021-0.7%-8.4%-10.4%
Q4 2020+1.7%+9.3%+1.2%
Q3 2020+2.0%+3.4%-0.9%
Q2 2020+14.3%+5.5%-1.9%
Q1 2020-1.4%+1.4%+2.9%
Q4 2019+10.4%+0.4%+0.2%
Q3 2019-3.2%-1.8%-19.8%
Q2 2019+0.2%-1.7%+2.7%
Q1 2019+1.5%-1.3%-12.8%
Q4 2018-4.4%-1.6%-6.3%
Q3 2018+8.4%+5.7%+29.1%
Q2 2018+0.3%+7.7%+1.4%
Q1 2018-0.5%+2.4%-3.9%
Q4 2017-0.6%-7.0%-2.3%
Q3 2017+2.8%-1.1%+3.9%
Q2 2017-1.6%-1.6%-1.9%
Q1 2017-0.3%+0.6%-8.0%
Q4 2016-0.6%+0.0%-4.1%
Q3 2016-5.7%+3.8%+54.8%
Q2 2016+4.5%+4.1%+11.4%
Q1 2016+1.1%
Q4 2015+1.1%
Q3 2015+2.4%
Q2 2015-0.9%
Q1 2015+5.7%
Q4 2014-1.3%
Q3 2014-0.7%
Q2 2014-4.9%
Q1 2014-1.4%
Q4 2013-2.7%
Q3 2013-3.5%
Q2 2013-2.8%
Q1 2011-2.4%
Q4 2012-2.5%
Q3 2012+6.5%
Q2 2012+5.3%
Q1 2012+4.5%
Q4 2011-1.4%
Q4 2009-1.4%
Q3 2010-6.1%
Q3 2011-6.1%
Q2 2011-12.0%
Q2 2010-12.0%
Q4 2010-12.0%
Q1 2010-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro